ClinicalTrials.gg
RecruitingNCT07146061Updated Oct 1, 2026

pCAD-POAF 3 Year Follow-up

An observational study in Coronary Artery Disease and Atrial Fibrillation, sponsored by China National Center for Cardiovascular Diseases. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by China National Center for Cardiovascular Diseases · Observational

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Oct 1, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
430
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Coronary Artery Disease by China National Center for Cardiovascular Diseases — 26 open to participants now, 27 under way, none of them phase 3. Coronary Artery Disease · China National Center for Cardiovascular Diseases.

Planned enrollment
14th of 25
430 · median 460
Started
2025
with 9 others
Observational
25 of 57
9 open now
Primary completion
2027-01
later than 12 of 26 live
Registered
42nd of 57
by date

Among the 57 studies in Coronary Artery Disease by China National Center for Cardiovascular Diseases, this one is the 14th largest by planned enrollment of the 25 observational ones that give a count, is one of 10 that started in 2025, is one of 25 observational ones, reaches primary completion later than 12 of the 26 other live ones, and was the 42nd registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

26 of the 57 studies in Coronary Artery Disease by China National Center for Cardiovascular Diseases are open now, in 1 country. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 26 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Coronary Artery Disease by China National Center for Cardiovascular Diseases, or all of them as a file.
02

Study summary

This study will include the subjects who enrolled in pCAD-POAF trial (NCT05009914) to observe clinical outcomes 3 years after surgery.

The primary outcome is the time to first occurrence of a composite of all-cause death, stroke, systemic embolism, myocardial infarction, unplanned cardiac rehospitalization, or post-discharge atrial fibrillation from randomization through 3 years after surgery.

The secondary outcomes are:the individual components of the primary composite outcome; unplanned all-cause rehospitalization; arrhythmias other than atrial fibrillation; premature atrial contraction and premature ventricular contraction burdens; heart rate variability parameters; quality-of-life scores; and other Holter-derived parameters.

Read the detailed description

This study aimed to observe clinical outcomes 3 years after surgery in patients enrolled in pCAD-POAF trial.

After completing the pCAD-POAF trial, investigators would not make any other interventions on enrolled patients. At the 3 year follow-up visit, all subjects will undergo regular laboratory test , electrocardiogram (ECG), ultrasound cardiography (UCG). Besides, coronary computed tomographic angiography(CCTA) will be performed depending on their own willingness. In the meantime, all subjects will be continuously monitored by wearing specific device for the detection of arrhythmias. Data collection will also include the use of medications, medical tests, any documented arrhythmias and the occurrence of clinical events within the 3 years.

In conclusion, this is a extensive follow-up of previous RCT and a non-interventional, observational study.

03

Conditions studied

  • Coronary Artery Disease
  • Atrial Fibrillation

Keywords

  • coronary artery disease
  • atrial fibrillation
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The population enrolled previously in pCAD-POAF trial.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • This study will include the subjects who enrolled in pCAD-POAF trial

Exclusion criteria

Exclusion Criteria:

  • This study will include the subjects who enrolled in pCAD-POAF trial
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
430 participants (estimated)
Patient registry
No

Groups and cohorts

  • Intervention group

    This group underwent partial cardiac denervation procedure as well as CABG in the pCAD-POAF trial. However, no other intervention was performed after completing the pCAD-POAF trial.

    Other: no other intervention

  • Control group

    This group only underwent CABG in the pCAD-POAF trial. Likewise, no other intervention was performed after completing the pCAD-POAF trial

    Other: no other intervention

Interventions

  • Otherno other intervention

    This is a observational study.

06

What researchers measure

Primary outcomes

  1. A composite of all-cause death, stroke, systemic embolism, myocardial infarction, unplanned cardiac rehospitalization, or post-discharge atrial fibrillation.

    The primary outcome was the time to first occurrence of a composite of all-cause death, stroke, systemic embolism, myocardial infarction, unplanned cardiac rehospitalization, or post-discharge atrial fibrillation from randomization through 3 years after surgery.

    Time frame: 3 year after the surgery

Secondary outcomes

  1. the individual components of the primary composite outcome

    the individual components of all-cause death, stroke, systemic embolism, myocardial infarction, unplanned cardiac rehospitalization, or post-discharge atrial fibrillation

    Time frame: within 3 year after surgery

  2. unplanned all-cause rehospitalization

    unplanned all-cause rehospitalization

    Time frame: within 3 year after surgery

  3. premature atrial contraction and premature ventricular contraction burdens

    premature atrial contraction and premature ventricular contraction burdens recorded by the 3-day continuous ECG monitoring

    Time frame: 3 year after surgery

  4. Holter-derived parameter, mean heart rate

    mean heart rate derived from the 3-day ECG monitoring

    Time frame: 3 year after the surgery

  5. Holter-derived parameter, HRV

    HRV derived from the 3-day ECG monitoring

    Time frame: 3 year after the surgery

  6. Assessment of quality of life

    Assessed by EQ-5D-5L (EuroQol 5-Dimensions 5-Levels questionnaire, higher score means better outcome) and AFEQT (Atrial-Fibrillation-Effect-on-Quality-of-life-Questionnaire, higher score means better outcome).

    Time frame: 3 year after the surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jan 2027, 17 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 17 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 28, 2025
StartActual
Aug 15, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 1, 2026
Sites
Fuwai Hospital, CAMS & PUMC is now Recruiting
Oct 1, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore AF burdenNow A composite of all-cause death, stroke, systemic embolism, myocardial infarction, unplanned cardiac rehospitalization, or post-discharge atrial fibrillation.Time frame: 3 year after the surgery
Oct 1, 2026
Secondary outcomes
5 added, 5 removed
What changed in the outcomes
  • Addedthe individual components of the primary composite outcomeTime frame: within 3 year after surgery
  • Addedunplanned all-cause rehospitalizationTime frame: within 3 year after surgery
  • Addedpremature atrial contraction and premature ventricular contraction burdensTime frame: 3 year after surgery
  • AddedHolter-derived parameter, mean heart rateTime frame: 3 year after the surgery
  • AddedHolter-derived parameter, HRVTime frame: 3 year after the surgery
  • RemovedFreedom of AF without the use of antiarrhymic medications or interventionsTime frame: within 3 year after surgery
  • RemovedThe occurence of MACCETime frame: within 3 year after surgery
  • RemovedAF incidence in 3 years and recorded by continuous ECG monitoringTime frame: 3 year after the surgery
  • RemovedPost-operative antiarrhythmic interventions and occurrence of arrhythmias other than AFTime frame: within 3 year after surgery
  • RemovedThe mean, maximum, and minimum heart rate and HRVTime frame: 3 year after the surgery
Oct 1, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Fuwai Hospital, CAMS & PUMC · Beijing, ChinaContact added f•••@fuwai.com · •••2265Contact added y•••@163.com · •••2265Contact added (no phone or email listed)Contact added (no phone or email listed)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Not yet recruiting→Recruiting
    Fuwai Hospital, CAMS & PUMC is now Recruiting
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore AF burdenNow A composite of all-cause death, stroke, systemic embolism, myocardial infarction, unplanned cardiac rehospitalization, or post-discharge atrial fibrillation.Time frame: 3 year after the surgery
    Secondary outcomes 5 added, 5 removed
    What changed in the outcomes
    • Addedthe individual components of the primary composite outcomeTime frame: within 3 year after surgery
    • Addedunplanned all-cause rehospitalizationTime frame: within 3 year after surgery
    • Addedpremature atrial contraction and premature ventricular contraction burdensTime frame: 3 year after surgery
    • AddedHolter-derived parameter, mean heart rateTime frame: 3 year after the surgery
    • AddedHolter-derived parameter, HRVTime frame: 3 year after the surgery
    • RemovedFreedom of AF without the use of antiarrhymic medications or interventionsTime frame: within 3 year after surgery
    • RemovedThe occurence of MACCETime frame: within 3 year after surgery
    • RemovedAF incidence in 3 years and recorded by continuous ECG monitoringTime frame: 3 year after the surgery
    • RemovedPost-operative antiarrhythmic interventions and occurrence of arrhythmias other than AFTime frame: within 3 year after surgery
    • RemovedThe mean, maximum, and minimum heart rate and HRVTime frame: 3 year after the surgery
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Fuwai Hospital, CAMS & PUMC · Beijing, ChinaContact added f•••@fuwai.com · •••2265Contact added y•••@163.com · •••2265Contact added (no phone or email listed)Contact added (no phone or email listed)
    + 3 other changes: verification date, date precision and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07146061
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Aug 15, 2025
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Wei Feng, MD
principal investigator · Chinese Academy of Medical Sciences, Fuwai Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion